Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product is Zofin, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins, and cell secreted nanoparticles; Patient Pure X, a proprietary autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood; and regenerative, anti-aging, and aesthetic medicine (RAAM) products and related services are used in the health care industry administered through doctors and clinics. It also provides SB 1768, which authorizes licensed physicians to administer certain stem cell therapies for use in the treatment of orthopaedic conditions, wound care, and pain management; HB 2246/SB 2586, Public Chapter 1016, which authorizes physicians to perform certain non-FDA-approved stem cell or regenerative medicine therapies; and HB 1275, Act 453, an establishing requirements for the use of certain human stem cell therapies. In addition, the company develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; and ZEO GROWX, ZEO HAIR GROW, and ZEO GROW BOOST, a serum comprised of hair growth stimulants for follicle stimulation. Further, it has a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes, and Whartons Jelly matrix. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is based in Davie, Florida.